Arizona State Retirement System Increases Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Arizona State Retirement System increased its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 1.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 16,187 shares of the company’s stock after purchasing an additional 308 shares during the period. Arizona State Retirement System’s holdings in Twist Bioscience were worth $798,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TWST. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $43,000. Blue Trust Inc. increased its stake in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after acquiring an additional 546 shares in the last quarter. CWM LLC boosted its position in shares of Twist Bioscience by 27.4% during the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after acquiring an additional 524 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Twist Bioscience during the first quarter worth about $124,000.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,114 shares of Twist Bioscience stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total transaction of $53,472.00. Following the sale, the chief executive officer now owns 504,732 shares of the company’s stock, valued at approximately $24,227,136. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Emily M. Leproust sold 1,114 shares of the firm’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $48.00, for a total value of $53,472.00. Following the completion of the transaction, the chief executive officer now owns 504,732 shares in the company, valued at approximately $24,227,136. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Dennis Cho sold 709 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the sale, the insider now directly owns 78,996 shares in the company, valued at $3,154,310.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,388 shares of company stock valued at $776,599. 3.92% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Guggenheim began coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price for the company. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Barclays lowered their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Finally, The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Trading Up 5.3 %

TWST opened at $46.95 on Friday. The company has a market cap of $2.75 billion, a P/E ratio of -13.97 and a beta of 1.76. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The business’s 50-day moving average price is $47.68 and its 200-day moving average price is $42.75.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. During the same quarter in the previous year, the firm posted ($1.01) EPS. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. Equities research analysts forecast that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.